Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Follitropin delta - Ferring Pharmaceuticals

Drug Profile

Follitropin delta - Ferring Pharmaceuticals

Alternative Names: FE-999049; Recombinant follicle-stimulating hormone - Ferring Pharmaceuticals; Recombinant FSH - Ferring; Rekovelle

Latest Information Update: 14 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Female infertility
  • Preregistration Male infertility

Most Recent Events

  • 16 Apr 2024 Ferring Pharmaceuticals completes a phase III ADAPT-1 trial for Female infertility (Combination therapy) in Austria, France, Germany, Italy, Spain and United Kingdom (SC) (EudraCT2021-001785-38) (NCT05263388)
  • 29 Mar 2024 Ferring Pharmaceuticals initiates the phase III COCO trial in Female infertility in China (SC) (NCT06173869)
  • 02 Jan 2024 Preregistration for Female infertility in USA (SC), before January 2024 (Ferring Pharmaceuticals pipeline, January 2024).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top